European Healthcare Tech M&A Advisory Shifts Toward Founder-Led Strategy

European healthcare technology and medical device advisory services are experiencing a fundamental transformation as founder-bankers replace traditional corporate financiers in guiding mid-market digital health and clinical AI transactions. The shift reflects growing recognition that conventional investment banking models focused on financial engineering fail to adequately assess clinical utility, regulatory requirements, and hospital procurement dynamics in healthtech deals. This realignment follows a period of speculative venture funding through 2022, market contraction due to rising interest rates, and the sector's evolution toward greater regulatory maturity and integration with public health infrastructure.

The advisory shift emerged from a distinct market cycle. During 2020-2022, when borrowing costs were minimal, investment firms with generalist expertise deployed capital across healthtech ventures, often applying standard software valuation methods that ignored clinical validation or hospital purchasing timelines. When interest rates rose sharply and capital became scarce, many of these loosely-vetted businesses contracted or failed, exposing gaps in traditional financial analysis applied to regulated medical sectors.

The transition reflects healthcare technology's maturation into infrastructure status. Modern healthtech assets require navigation of multiple regulatory regimes, integration with existing hospital systems, demonstration of measurable clinical outcomes, and compliance with data protection rules. Advisors with direct entrepreneurial experience in these constraints can better anticipate implementation challenges and structure deals that account for the operational realities that pure financial models often overlook.